KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Twist Bioscience (TWST) Other Non Operating Income (2017 - 2026)

Twist Bioscience has reported Other Non Operating Income over the past 10 years, most recently at $175000.0 for Q1 2026.

  • Quarterly Other Non Operating Income rose 144.42% to $175000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $230000.0 through Mar 2026, up 107.83% year-over-year, with the annual reading at -$903000.0 for FY2025, 66.29% up from the prior year.
  • Other Non Operating Income was $175000.0 for Q1 2026 at Twist Bioscience, down from $471000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $471000.0 in Q4 2025 and troughed at -$2.3 million in Q3 2024.
  • The 5-year median for Other Non Operating Income is -$199000.0 (2024), against an average of -$266941.2.
  • Year-over-year, Other Non Operating Income tumbled 831.2% in 2024 and then skyrocketed 606.45% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$157000.0 in 2022, then skyrocketed by 80.25% to -$31000.0 in 2023, then tumbled by 200.0% to -$93000.0 in 2024, then skyrocketed by 606.45% to $471000.0 in 2025, then plummeted by 62.85% to $175000.0 in 2026.
  • Per Business Quant, the three most recent readings for TWST's Other Non Operating Income are $175000.0 (Q1 2026), $471000.0 (Q4 2025), and $420000.0 (Q3 2025).